casimersen sold brand name amondys antisense oligonucleotide medication used treatment duchenne muscular dystrophy dmd people confirmed mutation dystrophin gene amenable exon antisense oligonucleotide phosphorodiamidate morpholino oligomer duchenne muscular dystrophy rare disease primarily affects caused low levels muscle protein called lack dystrophin causes progressive muscle weakness premature common side effects include upper respiratory tract infections cough fever headache joint pain throat casimersen approved medical use united states february first fdaapproved targeted treatment people confirmed mutation dmd gene amenable skipping exon casimersen indicated treatment duchenne muscular dystrophy dmd people confirmed mutation dmd gene amenable exon common side effects include headache fever joint pain cough cold duchenne muscular dystrophy xlinked recessive disorder results absence functional dystrophin dystrophin protein protein consists nterminal actinbinding domain cterminal bdystroglycan binding domain internal spectrumlike repeats dystrophin plays role muscle function without dystrophin muscle tissue replaced fibrous adipose tissue casimersen antisense phosphorodiamidate morpholino oligonucleotide designed bind exon dmd premrna prevents exclusion mature rna translation change causes production internally truncated dysphotrophin casimersen evaluated doubleblind placebocontrolled study participants randomized receive either intravenous casimersen participants male years age genetically confirmed mutation dmd gene amenable exon benefit evaluated measuring level dystrophin muscle biopsies participants treatment week interim trial conducted seven sites five countries united states canada germany spain czech us food drug administration fda granted application casimersen fast track priority review orphan drug fda granted approval amondys sarepta therapeutics httpsenwikipediaorgwikicasimersen